NDAINTRAVENOUSPOWDER
Approved
Jan 2005
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
ABRAXANE (paclitaxel) by Bristol Myers Squibb is depolymerization. Approved for breast cancer, non-small cell lung cancer, ovarian cancer and 1 more indications. First approved in 2005.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABRAXANE (paclitaxel) is an intravenous microtubule inhibitor approved by the FDA on January 7, 2005, for the treatment of breast cancer and lung cancer. The drug works by disrupting microtubule dynamics, inducing abnormal microtubule bundles that interfere with essential cellular functions during interphase and mitosis, ultimately triggering cancer cell death. ABRAXANE is indicated for metastatic breast cancer after failure of combination chemotherapy, relapsed disease within 6 months of adjuvant therapy, and as a treatment for advanced lung cancer, establishing it as a foundational chemotherapy agent in oncology.
$0.0BPart D
8.2 years to LOEMechanism of Action
depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple…
Pharmacologic Class:
Microtubule Inhibitor
Indications (4)
Worked on ABRAXANE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.